Panbela Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutics for patients with cancer, with a particular emphasis on pancreatic diseases such as pancreatitis and pancreatic cancer. They also develop treatments for other cancer-related conditions, including colorectal cancer and ovarian cancer. Their lead product candidate, SBP-101, is currently in Phase Ia/Ib clinical trials for the treatment of pancreatic ductal adenocarcinoma.